- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06332755
Étude pour évaluer le LB-LR1109 pour le traitement des tumeurs solides (LB-LR1109)
Une étude de phase 1, première chez l'homme, ouverte, multicentrique, à dose croissante pour évaluer l'innocuité, la tolérabilité, la pharmacocinétique et la pharmacodynamie du LB-LR1109 pour le traitement des tumeurs solides avancées ou métastatiques
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- NEXT Oncology
-
Contact:
- Alexander Spirra
- Numéro de téléphone: 703-783-4508
- E-mail: alexander.spira@usoncology.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
-
Age ≥18 years old at the time of signing the ICF.
-
(Phase 1a only) Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1,
- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.
-
(Phase 1a only) Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to approved therapies, or for which the participant refuses or is ineligible for standard therapy.
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
-
Life expectancy ≥12 weeks.
-
Participants with adequate organ function
-
No potential for childbearing or agree to use adequate contraception
-
Ability to understand the study purpose and procedures and have the willingness to sign a written informed consent document.
-
(Phase 1b only ) Must have histologically confirmed advanced or metastatic NSCLC without actionable genomic alteration that have approved therapies in the location where the participant's live and with measurable disease as determined by RECIST v1.1
Key Exclusion Criteria:
- Clinically significant cardiac disease or cardiac failure.
- Untreated or unstable brain or central nervous system (CNS) metastases or Leptomeningeal disease
- Participants with any concurrent active malignancies
- Has received prior therapy targeting LILRB or immunoglobulin-like transcript pathway.
- History of life-threatening toxicity related to prior immune therapy
- Has not recovered to ≤ Grade 1 or baseline from AEs and/or complications from prior surgical intervention or any anti-cancer treatment before starting study treatment
- Participants must not have an active, known, or suspected autoimmune disease.
- Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to initiation of study treatment therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry).
- Pregnant or lactating or expecting to conceive a child during the study or within 6 months after the last dose of study intervention.
- Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study intervention and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- (Phase 1b only) Participants who were previously exposed to atezolizumab
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: phase 1a : Escalade de dose / LB-LR1109 monothérapie
|
intravenous administration |
|
Expérimental: Phase 1b : Escalade de dose / LB-LR1109 en association avec l'Atezolizumab
|
intravenous administration |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC
Délai: through study completion, an average of 1year
|
Number of participants with dose-limiting toxicities (DLTs) |
through study completion, an average of 1year
|
|
Phase 1a: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as monotherapy / Phase 1b: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as combination therapy with atezolizumab
Délai: through study completion, an average of 1year
|
Incidence, severity (assessed by NCI CTCAE v5.0), and causality of AEs |
through study completion, an average of 1year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 1a / 1b: Preliminary efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Délai: through study completion, an average of 1year
|
ORR(overall response rate) assessed by RECIST v1.1 (%) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Antitumor efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Délai: through study completion, an average of 1year
|
PFS(Progression free survival) |
through study completion, an average of 1year
|
|
Phase 1a/1b: Antitumor efficacy of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Délai: through study completion, an average of 1year
|
OS (Overall survival) (months) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Pharmacokinetic profile of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Délai: through study completion, an average of 1year
|
Cmax (Maximum serum drug concentration) |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Characterize PK of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Délai: through study completion, an average of 1year
|
Area under the concentration-time curve (AUC) 0-last |
through study completion, an average of 1year
|
|
Phase 1a / 1b: Immunogenicity of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Délai: through study completion, an average of 1year
|
Number and percentage of participants with ADAs |
through study completion, an average of 1year
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Maladies pulmonaires
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Maladies de la peau
- Tumeurs urologiques
- Carcinome
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs rénales
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs neuroendocrines
- Nevi et mélanomes
- Tumeurs cutanées
- Carcinome épidermoïde
- Maladies de la peau et du tissu conjonctif
- Carcinome épidermoïde de la tête et du cou
- Carcinome à cellules rénales
- Carcinome pulmonaire non à petites cellules
- Mélanome
- Carcinome à cellules transitionnelles
- atézolizumab
Autres numéros d'identification d'étude
- LG-LRCL001
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .